Cumberland Pharmaceuticals Inc. (CPIX): Price and Financial Metrics


Cumberland Pharmaceuticals Inc. (CPIX)

Today's Latest Price: $3.20 USD

0.09 (-2.74%)

Updated Sep 29 4:00pm

Add CPIX to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 239 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

CPIX Stock Summary

  • Cumberland Pharmaceuticals Inc's market capitalization of $49,806,070 is ahead of only 14.07% of US-listed equities.
  • For CPIX, its debt to operating expenses ratio is greater than that reported by 28.77% of US equities we're observing.
  • Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for CPIX comes in at 13.12% -- higher than that of 83.65% of stocks in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Cumberland Pharmaceuticals Inc are MMSI, INTT, TACT, PLPC, and NSSC.
  • Visit CPIX's SEC page to see the company's official filings. To visit the company's web site, go to www.cumberlandpharma.com.
CPIX Daily Price Range
CPIX 52-Week Price Range

CPIX Stock Price Chart Technical Analysis Charts


CPIX Price/Volume Stats

Current price $3.20 52-week high $6.10
Prev. close $3.29 52-week low $3.10
Day low $3.18 Volume 6,099
Day high $3.25 Avg. volume 28,356
50-day MA $3.29 Dividend yield N/A
200-day MA $3.88 Market Cap 48.44M

Cumberland Pharmaceuticals Inc. (CPIX) Company Bio


Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on acquiring, developing, and commercializing branded prescription products for the hospital acute care and gastroenterology markets in the United States and internationally. The company was founded in 1999 and is based in Nashville, Tennessee.

CPIX Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$3.20$1.53 -54%

The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Cumberland Pharmaceuticals Inc. To summarize, we found that Cumberland Pharmaceuticals Inc ranked in the 27th percentile in terms of potential gain offered. Our DCF analysis suggests the stock is overvalued by about 53.33%. The most interesting components of our discounted cash flow analysis for Cumberland Pharmaceuticals Inc ended up being:

  • Interest coverage, a measure of earnings relative to interest payments, is -18.66; that's higher than only 7.22% of US stocks in the Healthcare sector that have positive free cash flow.
  • Cumberland Pharmaceuticals Inc's effective tax rate, as measured by taxes paid relative to net income, is at 0 -- greater than merely 0% of US stocks with positive free cash flow.


Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price
0%-54%
1%-54%
2%-54%
3%-53%
4%-53%
5%-52%

PKI, RMD, XRAY, ZTS, and ILMN can be thought of as valuation peers to CPIX, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.


CPIX Latest News Stream


Event/Time News Detail
Loading, please wait...

CPIX Latest Social Stream


Loading social stream, please wait...

View Full CPIX Social Stream

Latest CPIX News From Around the Web

Below are the latest news stories about Cumberland Pharmaceuticals Inc that investors may wish to consider to help them evaluate CPIX as an investment opportunity.

Newly Published Literature Supports Use Of Caldolor® For Postoperative Pain And Reduction Of Opioid Use

NASHVILLE, Tenn., Aug. 18, 2020 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, today announced the results of a new review of clinical studies evaluating Caldolor® (ibuprofen) Injection, which was published in the journal Clinical…

PR Newswire | August 18, 2020

Cumberland Pharmaceuticals Inc. 2020 Q2 - Results - Earnings Call Presentation

The following slide deck was published by Cumberland Pharmaceuticals Inc. in conjunction with their 2020 Q2 earnings call....

SA Transcripts on Seeking Alpha | August 12, 2020

Cumberland Pharmaceuticals, Inc. (CPIX) CEO A. J. Kazimi on Q2 2020 Results - Earnings Call Transcript

Cumberland Pharmaceuticals, Inc. (CPIX) Q2 2020 Earnings Conference Call August 11, 2020 04:30 PM ET Company Participants Erin Gull - IR A. J. Kazimi - CEO Marty Cearnal - Chief Commercial Officer Michael Bonner - CFO Conference Call Participants Andrew D'Silva - B. Riley FBR Presentation Operator Thanks to everyone...

SA Transcripts on Seeking Alpha | August 12, 2020

Caldolor® Demonstrates Significant Reduction Of Opioid Use In Orthopedic Trauma Patients

NASHVILLE, Tenn., July 20, 2020 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, today announced the results of a Level 1 Trauma Center study recently published in the Journal of Orthopedic Trauma. Results demonstrate Caldolor®…

PR Newswire | July 20, 2020

All You Need to Know About Cumberland (CPIX) Rating Upgrade to Buy

Cumberland (CPIX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 (Buy).

Yahoo | June 15, 2020

Read More 'CPIX' Stories Here

CPIX Price Returns

1-mo 0.00%
3-mo -3.91%
6-mo -11.36%
1-year -46.04%
3-year -54.67%
5-year -44.35%
YTD -37.86%
2019 -14.59%
2018 -18.07%
2017 33.82%
2016 4.56%
2015 -12.04%

Continue Researching CPIX

Here are a few links from around the web to help you further your research on Cumberland Pharmaceuticals Inc's stock as an investment opportunity:

Cumberland Pharmaceuticals Inc (CPIX) Stock Price | Nasdaq
Cumberland Pharmaceuticals Inc (CPIX) Stock Quote, History and News - Yahoo Finance
Cumberland Pharmaceuticals Inc (CPIX) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.8983 seconds.